Expression of hypoxia inducible factor-1α and its significance in laryngeal carcinoma

Journal of International Medical Research

Volumn 38, Issue 6, 2010, Pages 2040-2046

  Wu, X H ^a   Lu, Y F ^a   Hu, X D ^a   Mao, J Y ^b   Ji, X X ^b   Yao, H T ^a   Zhou, S H ^b  

^a Department of Otolaryngology ^*  (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Hypoxia inducible factor 1alpha; ; Immunohistochemistry; Laryngeal carcinoma; Tnm stage

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; DRINKING BEHAVIOR; GLOTTIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARYNX; LARYNX CARCINOMA; LYMPH NODE METASTASIS; MALE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOKING; SUPRAGLOTTIS;

EID: 78650807052     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800618     Document Type: Article

References (27)

1. Wang W, Xu GL, Jia WD, et al: Expression and 4 correlation of hypoxia-inducible factor-1α;, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res 2009;37:417-425.
2. McCarty MF, Barroso-Aranda J, Contreras F: Practical strategies for suppressing hypoxia- inducible factor activity in cancer therapy. Med Hypotheses 2010;74:789-797.
3. Seeber LM, Zweemer RP, Verheijen RH, et al: Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int 2010;2010:580971.
4. Seagroves TN, Ryan HE, Lu H, et al: Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells. Mol Cell Biol 2001;21: 3436-3444.
5. Berra E, Richard DE, Gothié E, et al: HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1-degradation. FEBS Lett 2001;491:85-90.
6. Talks KL, Turley H, Gatter KC, et al: The expression and distribution of the hypoxia- inducible factors HIF-1α;; and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000;157:411-421.
7. Shinohara ET, Maity A: Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumour microenvironment. Curr Mol Med 2009;9:1034-1045.
8. Rohwer N, Lobitz S, Daskalow K, et al: HIF-1α; determines the metastatic potential of gastric cancer cells. Br J Cancer 2009;100:772-781.
9. Cabanillas R, Rodrigo JP, Secades P, et al: The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer. J Surg Oncol 2009;99:373-378.
10. Winter SC, Shah KA, Han C, et al: The relation between hypoxia inducible factor (HIF)-1α; and HIF-2α; expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006;107:757-766.
11. Kyzas PA, Stefanou D, Batistatou A, et al: Hypoxia-induced tumour angiogenic pathway in head and neck cancer: an in vivo study. Cancer Lett 2005;225:297-304.
12. Beasley NJ, Leek R, Alam M, et al: Hypoxia- inducible factors HIF-1α and HIF-2α; in head and neck cancer: Relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002;62:2493-2497.
13. Yu L, Liu Y, Cui Y: Expression of hypoxia inducible factor-1alpha and its relationship to apoptosis and proliferation in human laryngeal squamous cell carcinoma. J Huazhong Univ Sci Technolog Med Sci 2004;24:636-638.
14. Schrijvers ML, van der Laan BF, de Bock GH, et al: Overexpression of intrinsic hypoxia markers HIF1α; and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:161-169.
15. Patel SG, Shah JP: TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005;55:242-258.
16. Cao D, Hou M, Guan YS, et al: Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer 2009;9:432.
17. Fillies T, Werkmeister R, van Diest PJ, et al: HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005;5:84.
18. Reynolds TY, Rockwell S, Glazer PM: Genetic instability induced by the tumour microenvironment. Cancer Res 1996;56:5754-5757.
19. Weidemann A, Johnson RS: Biology of HIF-1α;.Cell Death Differ 2008;15:621-627.
20. Nordsmark M, Eriksen JG, Gebski V, et al: Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 2007;83:389-397.
21. Kaanders JH, Wijffels KI, Marres HA, et al: Pimonidazole binding and tumour vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066-7074.
22. Koukourakis MI, Giatromanolaki A, Sivridis E, et al: Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;53:1192-1202.
23. Winter SC, Shah KA, Han C, et al: The relation between hypoxia-inducible factor (HIF)-1α; and HIF-2α; expression with anemia and outcome in surgically treated head and neck cancer. Cancer 2006;107:757-766.
24. Amann T, Hellerbrand C: GLUT1 as a therapeutic target in hepatocellular carcinoma.Expert Opin Ther Targets 2009;13:1411-1427.
25. Ogane N, Yasuda M, Shimizu M, et al: Clinicopathological implications of expressions of hypoxia-related molecules in esophageal superficial squamous cell carcinoma. Ann Diagn Pathol 2010;14:23-29.
26. Zhou S, Wang S, Wu Q, et al: Expression of glucose transporter-1 and -3 in the head and neck carcinoma - the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec 2008;70:189-194.
27. Zhou SH, Fan J, Chen XM, et al: Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 2009;31:1624-1633